Skip to content

Quick ratio at other companies

West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
0.0×
BridgeBio Pharma logo
BridgeBio PharmaBBIO
1.5×-3.1×
Arrowhead Research logo
Arrowhead ResearchARWR
6.2×+1.1×
AptarGroup logo
AptarGroupATR
1.1×+0.3×
AbbVie logo
AbbVieABBV
0.7×0.0×
Alkermes logo
AlkermesALKS
1.7×-1.2×

Other financials

Income statement

See full
Revenue$376.7M+42.2%
Gross profit$297.5M+37.4%
Operating income$184.5M+30.4%
Net income$150.0M+27.1%
EPS (diluted)$1.22+31.2%

Balance sheet

See full
Cash & equivalents$312.0M+76.9%
Total debt$2.2B+41.7%
Total equity$219.6M-54.5%
Total assets$2.7B+21.7%

Cash flow

See full
Operating cash flow$180.1M+16.8%
CapEx$3.7M+294%
Free cash flow$176.3M+15.0%

Valuation

See full
Market cap$8.13B-2.9%
Enterprise value$10B+3.0%
P/E13.4×-3.8×
P/S5.4×-2.3×

Profitability

See full
Gross margin82.8%-0.7pp
Operating margin59.3%+9.0pp
Net margin47.9%+6.5pp
FCF margin44.3%-1.5pp

Returns & leverage

See full
Return on equity124.5%+12.7pp
Debt / equity9.9×+6.7×
Current ratio2.8×-5.6×

Where this comes from

Calculated from Halozyme Therapeutics’s reported figures.

Based on the most recent quarter.

The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Halozyme Therapeutics's quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Halozyme Therapeutics's quick ratio?
Halozyme Therapeutics (HALO) reported quick ratio of 2.7× in Q1 2026.
How has Halozyme Therapeutics's quick ratio changed year-over-year?
Halozyme Therapeutics's quick ratio decreased by 66.7% year-over-year, from 8.2× to 2.7×.
What is the long-term trend for Halozyme Therapeutics's quick ratio?
Over 5 years (2020 to 2025), Halozyme Therapeutics's quick ratio has grown at a 31.1% compound annual growth rate (CAGR), from 1.2× to 4.5×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.